Celldex Therapeutics develops immunotherapies to treat specific forms of cancer, autoimmune diseases, and infections. The biopharmaceutical company's Precision Targeted Immunotherapeutics platform uses monoclanal antibodies, antibody-targeted vaccines, and immune system modulator to create disease-specific drugs. Two of its lead candidates are in clinical development for the treatment of brain cancer (CDX-110) and melanoma and breast cancer (CDX-011). Celldex takes candidates through earlier stages of development, then typically seeks partners to usher them through late stages. Formerly AVANT Immunotherapeutics, the company merged with Celldex Therapeutics in 2008 and took its name.